Month: November 2021

Resistance is Futile, For Now – Overcoming Resistance with Ceftazidime-Avibactam

I think we can all agree that resistance is inevitable, despite what the quote says, in the world of infectious diseases. More and more, the use of broad spectrum antibiotics (looking at you, vanco-zosyn!) brings upon more resistant organisms, with beta-lactamases being one of the key methods of resistance in many gram negative bacteria. As

Continue reading

Creep? The Implications of Rising MICs for Vancomycin in Staphylococcus Aureus

Look, I know I have talked a lot about staphylococcus but there is a ton of details that go into the therapeutic aspects of it.  When it comes to staphylococcus aureus bacteremia, specifically MRSA, vancomycin is the first line therapy per the IDSA guidelines (1). I have discussed the issues with vancomycin dosing, and how

Continue reading